Affinage

SIGLEC10

Sialic acid-binding Ig-like lectin 10 · UniProt Q96LC7

Length
697 aa
Mass
76.6 kDa
Annotated
2026-06-10
53 papers in source corpus 21 papers cited in narrative 23 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

Siglec-10 is a sialic acid-binding inhibitory receptor of the immune system that couples recognition of sialylated ligands on host and tumor cells to suppression of phagocytic, T cell, and innate inflammatory responses (PMID:11284738, PMID:31367043). Its membrane-distal V-set domain mediates calcium-dependent lectin activity toward both α2,3- and α2,6-linked sialoglycans, with crystallographic and NMR analyses localizing recognition to a non-conserved, selectivity-determining CC' loop and to binding-site arginines (R119, R127) that contact the sialic acid carboxyl group, while a hydrophobic domain 2 interface drives glycan-independent homodimerization required for cellular ligand engagement (PMID:41747717, PMID:32629603). Upon ligand binding, the cytoplasmic ITIM tyrosines are phosphorylated and recruit the phosphatases SHP-1 (via its N-terminal SH2 domain) and SHP-2, transducing the inhibitory signal in a manner analogous to other CD33-related Siglecs (PMID:11733002, PMID:12163025). Through these signals Siglec-10 enforces immune tolerance across multiple contexts: the receptor binds CD24 to deliver an anti-phagocytic 'don't eat me' signal that lets tumors evade macrophages (PMID:31367043), cooperates with HMGB1 to suppress DAMP-triggered NF-κB responses (PMID:19264983), and engages soluble CD52 (bridged by HMGB1) to block TCR-proximal Lck and Zap70 phosphorylation and dampen T cell activation (PMID:23685786, PMID:29997173). Additional sialylated ligands including integrin α3β1, endothelial VAP-1, and microbial pseudaminic acid extend this inhibitory axis to tumor-associated macrophages, leukocyte adhesion, and anti-inflammatory responses to bacterial flagellin (PMID:41182080, PMID:19861682, PMID:24823621, PMID:38372418). Siglec-10 expression in macrophages is directly activated by the transcription factor PU.1, and the receptor is co-opted as an endocytic entry receptor by PRRSV (PMID:41115355, PMID:28742001).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2001 High

    Established the founding identity of Siglec-10 as a sialic acid-binding inhibitory receptor, answering what kind of molecule it is and where it acts.

    Evidence cDNA cloning and expression in COS-7 cells with erythrocyte/sialoglycoconjugate binding assays and flow cytometry, replicated across labs

    PMID:11284738 PMID:11358961

    Open questions at the time
    • Structural basis of glycan recognition not defined
    • Physiological ligands and signaling consequences unknown
  2. 2001 High

    Defined the intracellular signaling logic by mapping the ITIM tyrosines and showing they recruit the inhibitory phosphatases SHP-1 and SHP-2.

    Evidence In vitro kinase assays with Y→F cytoplasmic mutants and cell-extract co-precipitation; SH2-domain pulldown mapping SHP-1 to a specific ITIM tyrosine

    PMID:11733002 PMID:12163025

    Open questions at the time
    • Tyrosine numbering conventions differ across studies
    • Cellular signaling outputs downstream of phosphatase recruitment not yet established
  3. 2009 High

    Connected Siglec-10 to selective suppression of danger-signal immunity, showing it partners with CD24 to dampen DAMP- but not PAMP-triggered NF-κB responses.

    Evidence CD24-deficient mouse model, co-immunoprecipitation of CD24 with Siglec-10/Siglec-G, NF-κB reporter and danger-vs-pathogen epistasis

    PMID:19264983

    Open questions at the time
    • Precise glycan epitope on CD24 not defined here
    • Direct phosphatase engagement in this pathway not measured
  4. 2009 Medium

    Extended Siglec-10's ligand repertoire to the endothelial enzyme VAP-1, implicating it in leukocyte adhesion and oxidative signaling.

    Evidence Phage display screening, adhesion assays, molecular modeling, and hydrogen peroxide production readout

    PMID:19861682

    Open questions at the time
    • Single lab without structural confirmation of the interface
    • Physiological relevance in vivo not established
  5. 2013 High

    Identified soluble CD52 as a Siglec-10 ligand that suppresses T cell activation, linking the receptor to TCR-proximal kinase inhibition.

    Evidence Co-IP, Lck/Zap70 phosphorylation assays, and phospholipase C-mediated CD52 release with binding to Siglec-10 on T cells

    PMID:23685786

    Open questions at the time
    • Mechanism bridging CD52 to Siglec-10 not yet resolved
    • Single-lab functional data
  6. 2014 Medium

    Demonstrated that microbial sialic-acid mimics (pseudaminic acid on C. jejuni flagellin) exploit Siglec-10 to drive anti-inflammatory IL-10, revealing pathogen subversion of the receptor.

    Evidence Isogenic flagellin mutants, Siglec-10 overexpression, IL-10 ELISA, and p38 inhibitor experiments with purified flagellum binding

    PMID:24823621

    Open questions at the time
    • Relies on overexpression rather than endogenous receptor
    • ITIM/phosphatase requirement not tested
  7. 2016 Medium

    Established selectivity and tissue context of the CD24–Siglec-10 interaction at the fetal-maternal interface.

    Evidence Affinity-purified placental CD24, ELISA binding to recombinant Siglecs with Siglec-3/-5 negative controls, EDTA inhibition, and co-localization imaging

    PMID:28012129

    Open questions at the time
    • Functional consequence at the decidua not tested
    • Single lab
  8. 2018 High

    Resolved the CD52 suppression mechanism by showing HMGB1 bridges CD52 glycan to Siglec-10, triggering ITIM phosphorylation, SHP-1 recruitment, and TCR association.

    Evidence Reciprocal Co-IP of the Siglec-10/HMGB1/SHP1/TCR complex, HMGB1 Box A vs Box B domain mapping, antibody blocking, and α2,3-sialic-acid glycan specificity

    PMID:29997173

    Open questions at the time
    • In vivo relevance of the ternary complex not shown
    • Single lab
  9. 2019 High

    Defined CD24–Siglec-10 as a macrophage 'don't eat me' checkpoint exploited by tumors, establishing therapeutic blockade as a strategy.

    Evidence CRISPR KO of CD24 and Siglec-10, antibody blockade, phagocytosis assays, in vivo xenografts and macrophage depletion

    PMID:31367043

    Open questions at the time
    • Phosphatase-dependence of the anti-phagocytic signal not directly tested here
    • Range of tumor-cell glycan ligands not enumerated
  10. 2020 Medium

    Provided the first structural/biophysical models of Siglec-10 glycan recognition and showed a V-set point mutation (R47Q) impairs ligand binding.

    Evidence STD-NMR, MD simulations and docking for α2,3/α2,6 sialoglycans; recombinant R47Q and A108V variant binding assays with homology modeling

    PMID:32629603 PMID:33223341

    Open questions at the time
    • No crystal structure at this stage
    • Functional consequences of variants in primary cells not tested
  11. 2023 Medium

    Linked macrophage Siglec-10 to suppression of CD8+ T cell function via Akt/p38/Erk signaling, broadening its role in the tumor microenvironment.

    Evidence Macrophage–CD8 T cell co-culture, signaling inhibitors, ex vivo and in vivo blockade

    PMID:37432407

    Open questions at the time
    • Receptor-intrinsic signaling steps not dissected
    • Single lab
  12. 2024 Medium

    Expanded the ligand and disease repertoire to dendritic-cell tolerance (galectin-9), CLL CAR-T suppression (CD24/CD52), and macrophage pseudaminic-acid sensing driving IL-10 and phagocytosis blockade.

    Evidence scRNA-seq and tumor-fragment blockade in cervical cancer; CLL/CAR-T co-culture with CD40 stimulation and SRC inhibition; Pse–Siglec-10 binding, IL-10 ELISA and phagocytosis assays with ligand blockade

    PMID:38372418 PMID:39042920 PMID:39209455

    Open questions at the time
    • Mechanistic coupling of these ligands to ITIM signaling not directly shown
    • Each finding from a single lab
  13. 2025 Medium

    Identified PU.1 as a direct transcriptional driver of macrophage Siglec-10, explaining how its expression is established and linking it to phagocytic control of glioma.

    Evidence Luciferase reporter and ChIP assays, PU.1 knockdown, phagocytosis assays, in vivo glioma model

    PMID:41115355

    Open questions at the time
    • Other transcriptional regulators not assessed
    • Single lab
  14. 2026 High

    Delivered the crystallographic basis of ligand selectivity and dimerization, showing the CC' loop determines glycan selectivity and a D2 hydrophobic interface mediates homodimerization essential for cellular binding.

    Evidence X-ray structures of Siglec-10/sialyllactose complexes with mutagenesis of the CC' loop, glycan site, and D2 interface, plus cell-based and CD24-KO binding validation

    PMID:41747717

    Open questions at the time
    • How dimerization is regulated on the cell surface in physiological signaling not fully defined
  15. 2026 High

    Identified integrin α3β1 as a sialylated tumor-cell ligand engaging macrophage Siglec-10 to block phagocytosis in PDAC, validated in humanized models.

    Evidence Glycoproteomic ligand identification, co-culture phagocytosis assays, antibody blockade, PDAC xenografts and human Siglec-10 transgenic mice

    PMID:41182080

    Open questions at the time
    • Relative contribution of integrin α3β1 vs CD24 in different tumors not ranked
    • Downstream phosphatase signaling not dissected here
  16. 2025 High

    Refined the structural binding mechanism, defining arginines R119/R127 with distinct solution vs cellular roles, demonstrating glycan-independent dimerization on monocytes, and identifying additional T-cell sialoglycoprotein ligands beyond CD24.

    Evidence X-ray crystallography with α2,6-sialyllactose, STD-NMR, R119A/R127A mutagenesis, cell binding on primary T cells and monocytes, super-resolution microscopy, and proximity-labeling MS (preprint)

    Open questions at the time
    • Preprint not yet peer-reviewed
    • Identity and function of the newly mapped T-cell ligands not yet characterized

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the multiple ligand engagements, surface dimerization state, and ITIM/SHP signaling are quantitatively integrated to set inhibitory thresholds across distinct cell types remains unresolved.
  • No unified model linking ligand identity to differential phosphatase output
  • Cell-type-specific signaling logic not mapped
  • In vivo hierarchy of competing ligands unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3 GO:0098772 molecular function regulator activity 3 GO:0001618 virus receptor activity 1 GO:0140110 transcription regulator activity 1
Localization
GO:0005886 plasma membrane 3
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3
Partners
CD24CD52HMGB1ITGA3ITGB1SHP-1SHP-2VAP-1

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 Siglec-10 is a sialic acid-binding inhibitory receptor containing five extracellular Ig-like domains and a cytoplasmic tail with ITIM signaling motifs; the expressed protein mediates sialic acid-dependent binding to human erythrocytes and soluble sialoglycoconjugates, and is detected on eosinophils, monocytes, and NK-like cells. cDNA cloning, expression in COS-7 cells, binding assays with erythrocytes and sialoglycoconjugates, flow cytometry with specific antibodies The Biochemical journal High 11284738
2001 The cytoplasmic ITIM tyrosines Y597 and Y667 of Siglec-10 are the principal phosphorylation sites; SHP-1 interacts with Y667 and SHP-2 interacts with Y667 and an additional tyrosine, indicating inhibitory signaling analogous to CD33. In vitro kinase assay with wild-type and Y→F mutant cytoplasmic domain constructs; cell extract co-precipitation European journal of biochemistry High 11733002
2001 Siglec-10 expressed on COS-7 cells binds human red blood cells and soluble sialoglycoconjugates in a sialic acid-dependent manner, consistent with its V-set domain mediating lectin activity. Transfection of COS-7 cells with Siglec-10 cDNA; erythrocyte binding assay; inhibition with sialic acid The Journal of biological chemistry High 11358961
2002 SHP-1 recruitment to the Siglec-10 cytoplasmic tail requires tyrosine phosphorylation and is mediated specifically through ITIM tyrosine Y609 and the N-terminal SH2 domain of SHP-1; Siglec-10 does not bind SAP/SH2D1A, distinguishing the CD150-like motif as a docking site for other mediators. Yeast three-hybrid cloning of splice variant; Western blot; ITIM mutational analysis (Y→F substitutions); SH2-domain pulldown Biochemical and biophysical research communications High 12163025
2009 CD24 associates with the DAMPs HMGB1, HSP70, and HSP90, negatively regulates their stimulatory activity, and inhibits NF-κB activation; this occurs through CD24 association with Siglec-10 (in humans) or Siglec-G (in mice), selectively suppressing danger- but not pathogen-associated molecular pattern-triggered innate immune responses. CD24-deficient mouse model; co-immunoprecipitation; NF-κB reporter assays; genetic epistasis (CD24-KO × DAMP challenge vs. PAMP challenge) Science High 19264983
2009 Siglec-10 functions as a leukocyte ligand for endothelial VAP-1 (SSAO enzyme); binding was identified by phage display and confirmed by adhesion assays and molecular modeling; interaction leads to increased hydrogen peroxide production, indicating Siglec-10 serves as a VAP-1 substrate. Phage display screening; cell adhesion assays; molecular modeling; hydrogen peroxide production assay Blood Medium 19861682
2013 Soluble CD52, released from activated T cells by phospholipase C cleavage, binds to Siglec-10 on T cells and impairs phosphorylation of TCR-associated kinases Lck and Zap70, thereby suppressing T cell activation. Co-immunoprecipitation; phosphorylation assays (Lck, Zap70); soluble CD52 binding to Siglec-10 on T cells; phospholipase C treatment Nature immunology High 23685786
2014 Pseudaminic acid residues on Campylobacter jejuni flagellin (FlaA) bind to Siglec-10 on dendritic cells; Siglec-10 overexpression in cells infected with C. jejuni increases IL-10 expression in a p38 MAPK-dependent manner, establishing a novel anti-inflammatory flagellin–host receptor axis. C. jejuni isogenic flagellin mutants; Siglec-10 overexpression in cell lines; IL-10 ELISA; p38 inhibitor experiments; direct binding assay with purified flagellum The Journal of infectious diseases Medium 24823621
2018 CD52-mediated T cell suppression via Siglec-10 requires HMGB1 as a bridging molecule: CD52-Fc binds specifically to the proinflammatory Box B domain of HMGB1, which promotes engagement of the CD52 N-linked glycan (α-2,3 sialic acid linked to galactose) with Siglec-10; this triggers Siglec-10 tyrosine phosphorylation, SHP1 recruitment to the Siglec-10 ITIM, and physical association of the complex with the TCR. Co-immunoprecipitation (Siglec-10/HMGB1/SHP1/TCR complex); domain-mapping with Box A vs. Box B HMGB1 constructs; anti-HMGB1 antibody blocking; Siglec-10 phosphorylation assay; glycan-binding specificity (EDTA, α-2,3 sialic acid) Proceedings of the National Academy of Sciences of the United States of America High 29997173
2019 CD24 acts as an anti-phagocytic 'don't eat me' signal on tumor cells by engaging Siglec-10 on tumor-associated macrophages; genetic ablation of either CD24 or Siglec-10, or antibody blockade of their interaction, robustly augments macrophage phagocytosis of CD24-expressing human tumors and reduces tumor growth in vivo. Genetic ablation (CRISPR KO of CD24 or Siglec-10); monoclonal antibody blockade; phagocytosis assay; in vivo xenograft tumor models; macrophage depletion Nature High 31367043
2016 Placental CD24 interacts with Siglec-10 via terminal sialic acid glycan residues in an EDTA-sensitive manner; CD24 does not interact with Siglec-3 or Siglec-5, establishing selectivity of the CD24–Siglec-10 interaction; co-localization of CD24 and Siglec-10 was observed in first-trimester decidual cells at the fetal–maternal interface. Affinity purification of placental CD24; ELISA-based binding assay with recombinant Siglecs; EDTA inhibition; immunohistochemistry and immunofluorescence co-localization Histochemistry and cell biology Medium 28012129
2017 Porcine Siglec-10 functions as an alternative receptor for PRRSV entry; Siglec-10 expression in CD163-transfected PK15 cells significantly enhances PRRSV infection and production, and Siglec-10 mediates endocytosis of the virus. Transfection of PK15 cells with porcine Siglec-10 + CD163; virus infection and production assays (TCID50); endocytosis assay The Journal of general virology Medium 28742001
2020 The R47Q substitution (but not A108V alone) in the ligand-binding V-set domain of Siglec-10 impairs ganglioside binding, as shown by recombinant protein binding assays; homology modeling revealed marked alteration in the ligand-binding site at position 47. Recombinant Siglec-10 protein with R47Q and A108V variants; ganglioside binding assay; homology modeling of ligand-binding site Journal of autoimmunity Medium 33223341
2020 Siglec-10 molecular recognition of sialoglycans was characterized by combined NMR spectroscopy (STD-NMR), computational modeling, and biophysical approaches; Siglec-10 binds α2,3- and α2,6-linked sialoglycans with defined epitope-mapping and conformational features, providing the first structural insights into its glycan recognition mechanism. STD-NMR; computational (MD simulations, docking); biophysical binding assays iScience Medium 32629603
2023 SIGLEC10 in macrophages suppresses CD8+ T cell proliferation and function via the Akt/P38/Erk signaling pathway; SIGLEC10 blockade promotes CD8+ T cell effector function in ex vivo and in vivo models. In vitro co-culture of SIGLEC10+ macrophages with CD8+ T cells; signaling pathway inhibitors; ex vivo tumor models; in vivo blockade Cancer immunology, immunotherapy : CII Medium 37432407
2024 Bacterial pseudaminic acid (Pse) on exopolysaccharide engages Siglec-10 on macrophages via the 7-N-acetyl group of Pse, stimulating IL-10 secretion that suppresses phagocytosis; blockade of Pse–Siglec-10 interaction with Pse-binding protein reverses this effect. Pse-Siglec-10 binding assay; IL-10 ELISA; phagocytosis assay; blocking with Pse-binding protein Chemical communications Medium 38372418
2024 Siglec-10 on dendritic cells in cervical cancer senses aberrant sialylated structures on tumor cells, inducing transformation of conventional DCs into immunotolerant phenotypes; Siglec-10+ DCs suppress adaptive T cells via galectin-9 signaling; Siglec-10 blockade restores DC-mediated tumoricidal responses. Single-cell RNA sequencing; patient-derived tumor fragment platform; Siglec-10 blockade assays; T cell activation readouts Journal for immunotherapy of cancer Medium 39209455
2024 CLL cells suppress CAR T cell function via surface expression of Siglec-10 ligands CD24 and CD52; blocking CD24 and/or CD52 markedly reduces CAR T cell dysfunction upon co-culture, and CD40 activation of CLL cells downregulates these ligands via an SRC kinase-dependent pathway. Co-culture of CLL cells with CAR T cells; CD40 stimulation; SRC kinase inhibitor (dasatinib); antibody blockade of CD24/CD52; transcriptome profiling Blood advances Medium 39042920
2025 PU.1 transcription factor in macrophages directly targets and transcriptionally activates Siglec-10 expression (demonstrated by luciferase and ChIP assays), suppressing macrophage phagocytosis; PU.1 knockdown in macrophages increases phagocytic activity and inhibits glioma growth in vivo. Luciferase reporter assay; chromatin immunoprecipitation (ChIP); PU.1 knockdown; phagocytosis assay; in vivo glioma model International immunopharmacology Medium 41115355
2026 Crystal structures of Siglec-10 bound to α2,3- and α2,6-sialyllactose reveal that domain 1 (D1) engages sialylated ligands via a non-conserved, selectivity-determining CC' loop; Siglec-10 homodimerization is mediated by a hydrophobic domain 2 (D2) interface, and mutation of the D2 interface ablates cellular binding equivalently to mutations in the CC' loop and glycan-binding site. X-ray crystallography (Siglec-10/sialyllactose complex); mutagenesis of D2 dimerization interface and CC' loop; cell-based binding assays; CD24 KO binding experiments Structure High 41747717
2026 Integrin α3β1 (composed of ITGA3 and ITGB1) on pancreatic ductal adenocarcinoma (PDAC) cells is a sialylated glycoprotein ligand for Siglec-10 on tumor-associated macrophages; this interaction suppresses macrophage-mediated phagocytosis; antibody blockade of Siglec-10 enhances phagocytosis in vitro and reduces tumor growth in xenograft and human Siglec-10 transgenic mouse models. Ligand identification (glycoproteomic/interaction approach); co-culture phagocytosis assay; monoclonal antibody blockade; PDAC xenograft with human macrophages; human Siglec-10 transgenic mouse model Cancer research High 41182080
2025 Crystal structure of the Siglec-10 extracellular domain in complex with α2-6 sialyllactose identified two key arginine residues (R119 and R127) in the binding site that interact with the sialic acid carboxyl group; STD-NMR confirmed R119 is essential for sialoglycan binding in solution, while R127 is dispensable in solution but required for cellular recognition on primary human T cells and engineered monocytic lines; super-resolution microscopy revealed glycan-independent Siglec-10 dimerization on human monocytes; proximity labeling/MS identified additional sialylated glycoproteins as Siglec-10 ligands on T cells beyond CD24. X-ray crystallography; STD-NMR; point mutagenesis (R119A, R127A); cell-based binding assays on primary T cells and monocytes; super-resolution microscopy; proximity labeling + mass spectrometry bioRxivpreprint High
2024 Soluble CD52 immunosuppressive function via Siglec-10 requires hyper-sialylated glycans; the N-linked glycan at N3 with α-2,3-linked sialic acid is essential for Siglec-10 binding; molecular dynamics simulations defined specific interactions between CD52 glycans and the Box B domain of HMGB1 that stabilize the CD52/HMGB1 complex required for Siglec-10 engagement. High-resolution mass spectrometry of CD52 glycopeptides; molecular dynamics simulation of CD52/HMGB1/Siglec-10 ternary complex; glycan characterization bioRxivpreprint Medium

Source papers

Stage 0 corpus · 53 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 1117 31367043
2009 CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science (New York, N.Y.) 672 19264983
2013 T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nature immunology 165 23685786
2001 Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor. The Biochemical journal 99 11284738
2020 Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10. Frontiers in immunology 82 32765491
2001 A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33. European journal of biochemistry 82 11733002
2001 Cloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells. The Journal of biological chemistry 77 11358961
2009 Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate. Blood 76 19861682
2018 CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function. Proceedings of the National Academy of Sciences of the United States of America 70 29997173
2014 Pseudaminic acid on Campylobacter jejuni flagella modulates dendritic cell IL-10 expression via Siglec-10 receptor: a novel flagellin-host interaction. The Journal of infectious diseases 67 24823621
2014 Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma. The Journal of surgical research 61 25450598
2023 Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy. Journal for immunotherapy of cancer 57 37344099
2024 Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Cancer immunology, immunotherapy : CII 53 38279998
2021 Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma. Experimental hematology & oncology 51 34112250
2023 Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 50 36866919
2016 Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface. Histochemistry and cell biology 47 28012129
2003 Molecular analysis of human Siglec-8 orthologs relevant to mouse eosinophils: identification of mouse orthologs of Siglec-5 (mSiglec-F) and Siglec-10 (mSiglec-G). Genomics 43 14559209
2022 GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis. Molecular pharmaceutics 36 36547230
2019 Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression. Cancer management and research 32 31534365
2017 Molecular cloning of porcine Siglec-3, Siglec-5 and Siglec-10, and identification of Siglec-10 as an alternative receptor for porcine reproductive and respiratory syndrome virus (PRRSV). The Journal of general virology 31 28742001
2020 Siglec-10 expression is up-regulated in activated human CD4+ T cells. Human immunology 29 32046870
2020 Unveiling Molecular Recognition of Sialoglycans by Human Siglec-10. iScience 28 32629603
2002 Cloning of two new splice variants of Siglec-10 and mapping of the interaction between Siglec-10 and SHP-1. Biochemical and biophysical research communications 27 12163025
2018 Preferential use of Siglec-1 or Siglec-10 by type 1 and type 2 PRRSV strains to infect PK15S1-CD163 and PK15S10-CD163 cells. Veterinary research 24 30021620
2023 Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer. Journal for immunotherapy of cancer 21 37935567
2022 Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient samples. Frontiers of medicine 17 35075579
2024 T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells. Blood advances 15 39042920
2024 Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy. Journal for immunotherapy of cancer 15 39209455
2023 SLG2 specifically regulates grain width through WOX11-mediated cell expansion control in rice. Plant biotechnology journal 15 37340997
2001 Molecular characterization, tissue expression, and mapping of a novel Siglec-like gene (SLG2) with three splice variants. Biochemical and biophysical research communications 15 11409878
2025 Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors. Journal for immunotherapy of cancer 14 40169285
2023 SIGLEC10+ macrophages drive gastric cancer progression by suppressing CD8+ T cell function. Cancer immunology, immunotherapy : CII 14 37432407
2020 A Guillain-Barré syndrome-associated SIGLEC10 rare variant impairs its recognition of gangliosides. Journal of autoimmunity 14 33223341
2024 Unravelling CD24-Siglec-10 pathway: Cancer immunotherapy from basic science to clinical studies. Immunology 13 39129256
2014 Molecular characterization of porcine Siglec-10 and analysis of its expression in blood and tissues. Developmental and comparative immunology 13 25280627
2024 Bacterial pseudaminic acid binding to Siglec-10 induces a macrophage interleukin-10 response and suppresses phagocytosis. Chemical communications (Cambridge, England) 7 38372418
2024 Chitinase 3-like-1 Inhibits Innate Antitumor and Tissue Remodeling Immune Responses by Regulating CD47-SIRPα- and CD24-Siglec10-Mediated Phagocytosis. Journal of immunology (Baltimore, Md. : 1950) 7 39291933
2026 Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. Cancer research 5 41182080
2021 Elevated CD19+Siglec-10+ B cell levels are correlated with systemic lupus erythematosus disease activity. International immunopharmacology 5 34857478
2025 Signal Transducer Nanoparticles Enable Siglec-10/G Blockade Immunotherapy for Breast Cancer Treatment. Advanced materials (Deerfield Beach, Fla.) 4 40619860
2025 Targeting Siglec-10/α3β1 Integrin Interactions Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. bioRxiv : the preprint server for biology 3 40654843
2026 Mitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor models. Scientific reports 2 41606146
2025 Circulating CD24/Siglec-10 biomarkers predict post-resuscitation outcomes in a cardiac arrest cohort. Scientific reports 2 41162542
2025 Nebulized macrophage membrane-engineered triptolide liposomes for Siglec-10/CD24-mediated therapeutic targeting in lung cancer. International journal of pharmaceutics: X 2 41404373
2025 Progression of glioma through PU.1-mediated suppression of macrophage phagocytosis via targeting Siglec-10. International immunopharmacology 1 41115355
2024 Expression of the mucin-like glycoprotein CD24 and its ligand siglec-10 in placentas with acute and post SARS-CoV-2 infection. Journal of reproductive immunology 1 39612561
2024 The expression of Siglec-10 on naive B cells is involved in the pathology of systemic lupus erythematosus. Clinical and experimental rheumatology 1 39711368
2026 Structural basis for sialoglycan recognition by the immune inhibitory receptor Siglec-10. Structure (London, England : 1993) 0 41747717
2026 Chemoradiotherapy facilitates siglec-10+/siglec-9+ macrophage-mediated impairment of CD24+/MUC16+ tumor cell elimination and enhances PD-L2 dependent immunosuppression in cervical cancer. Cancer immunology, immunotherapy : CII 0 41801406
2026 Accumulation of Siglec10+CX3CR1+ Macrophages in the Tumor Microenvironment of Glioblastomas. European journal of immunology 0 42003504
2025 Commentary on "Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors". Journal for immunotherapy of cancer 0 40518291
2025 First Evidence of Siglec-10 Localization and Expression in Camel Male Reproductive Tissues and Spermatozoa: Potential Relevance to Fertility. Veterinary sciences 0 41295701
2023 High Expression and Significance of Siglec10/CD24 in Unexplained Missed Abortion. Immunological investigations 0 37933581

Missed literature

Know a paper Affinage missed for SIGLEC10? Flag it for the maintainers and the community.

No submissions yet.